US20140341801A1 - Inactivation of smooth muscle tissue - Google Patents
Inactivation of smooth muscle tissue Download PDFInfo
- Publication number
- US20140341801A1 US20140341801A1 US14/447,098 US201414447098A US2014341801A1 US 20140341801 A1 US20140341801 A1 US 20140341801A1 US 201414447098 A US201414447098 A US 201414447098A US 2014341801 A1 US2014341801 A1 US 2014341801A1
- Authority
- US
- United States
- Prior art keywords
- agent
- smooth muscle
- airway
- blood
- lung
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A61K47/48438—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C07K2316/96—
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- Asthma is a serious chronic condition. In the United States alone, it is believed that asthma affects upward of 15 million Americans. Asthma is characterized by (i) bronchoconstriction, (ii) excessive mucus production, and (iii) inflammation and swelling of airways. These conditions cause widespread and variable airflow obstruction thereby making it difficult for the asthma sufferer to breathe. Asthma further includes acute episodes or attacks of additional airway narrowing via contraction of hyper-responsive airway smooth muscle. Other obstructive diseases such as COPD may also have a reversible component caused by one or more of the above mentioned three elements.
- Asthma generally includes excessive mucus production in the bronchial tree.
- Excessive amounts of mucus are found in the airways and semisolid plugs of mucus may occlude some small bronchi.
- the small airways are narrowed and may show inflammatory changes. See, e.g., Kraft M, The Distal Airways: Are they Important in Asthma? Eur Respir J 1999; 14:1403-1417.
- the reversible aspects of COPD include partial airway occlusion by excess secretions, bronchial wall edema, inflammation of the airways and airway narrowing as a result of smooth muscle contraction.
- Stimulus avoidance includes systematic identification of each type of stimuli and minimization of contact with each type of stimuli. It may, however, be impractical and not always helpful to avoid all potential stimuli.
- Pharmacological mediation of asthma includes: (1) long term control through use of anti-inflammatories and long-acting bronchodilators and (2) short term management of acute exacerbations through use of short-acting bronchodilators. Both approaches require repeated and regular use of the prescribed drugs. High doses of corticosteroid anti-inflammatory drugs may include serious side effects requiring careful management. In addition, some patients are resistant to steroid treatment.
- Removal and/or deactivation of a body organ, vestigial or not, is medically acceptable as long as there is an overall benefit.
- a few examples of such procedures include removal of: body hair, the appendix, wisdom teeth, and portions of the cornea.
- deactivation of certain muscles is accepted for cosmetic results.
- a physician injects botulism toxin type A (i.e., BOTOX®) directly into the corrugator and procerus muscles, preventing them from contracting and eventually causing the skin to become smoother,
- botulism toxin type A i.e., BOTOX®
- the present invention includes methods of treating smooth muscle tissue to prevent adverse effects resulting from constriction of body passages.
- approaches discussed below discuss treatment of airway smooth muscle to prevent bronchoconstriction in cases of pulmonary disorders, it is contemplated that variations of the treatment are not limited to airway smooth muscle. Variations of the treatments and procedures described herein may be applied to non-airway smooth muscle where appropriate.
- the treatments and procedures described below include methods of treating individual for hyper-responsiveness of a body passage, where the method comprises placing an agent into a blood vessel that supplies blood to tissue of the body passage, where the agent affects'the ability of the body passage to constrict.
- altering a blood supply of smooth muscle tissue in the body passage may include adding an agent to the blood that affects smooth muscle as discussed herein.
- altering of the blood flow may comprise slowing or stopping the flow of blood to the target smooth muscle to affect the smooth muscle tissue.
- the agents described herein may include toxins, radioactive agents, viral agents, and/or drugs.
- Example of such agents includes toxins such as natural, animal or insect toxins, or engineered toxins; I-131 (Iodine 131), laser absorptive dye, agents that bind to constituents of airway smooth muscle (e.g., myosin, actin), neutrophils, paralytic agents, embolizing agents, etc.
- agents that selectively affect smooth muscle tissue include: snake myotoxins; anti-bodies that bind to actin or myosin, with the impairment agent bound to the antibody.
- the agent may also include microspheres the size of the capillaries at the smooth muscle. These micropspheres could also contain an additional agent.
- Variations of the invention described herein include procedures and treatments that deliver a persistent treatment to prevent the ability of body passages to constrict.
- FIG. 1 is a cross sectional view of an airway in a healthy lung.
- FIG. 2 shows a section through a bronchiole having an airway diameter smaller than that shown in FIG. 1 .
- FIG. 3 illustrates an airway similar to that of FIG. 1 but in which the smooth muscle hypertrophied and increased in thickness causing reduction of the airway diameter.
- FIG. 4 is a representation of the lungs, airway, pulmonary vessels and bronchial vessels.
- FIG. 5 is a representation of the bronchial artery and vein as it runs along an airway.
- the invention relates to reducing or preventing a body passage from constricting by inactivating or therapeutically damaging the smooth muscle which causes contraction of the body passage.
- the invention described herein may have applications throughout the body, the variation of the invention described below relates to treating airway smooth muscle tissue to prevent or reduce constriction of the airways within a lung. As noted above, preventing or reducing constriction of the airways allows for improved breathing for individual suffering from a pulmonary condition, such as asthma.
- the inventive treatment reduces the ability of the airways to constrict, narrow or to reduce in diameter due to airway smooth muscle contraction.
- the reduction in the ability of the smooth muscle to contract may lie achieved by treating the smooth muscle itself or by treating other tissues to affect smooth muscle contraction or the response of the airway to the smooth muscle contraction. Treatment may also reduce airway responsiveness or the tendency of the airway, to narrow or to constrict in response to a stimulus.
- the reduction in smooth muscle and surrounding tissue may also have the added potential benefit of increasing the caliber or diameter of the airways, this benefit reduces the resistance to airflow through the airways.
- the devices and/or approach of the present invention may eliminate smooth muscle altogether by damaging or destroying the muscle.
- the smooth muscle is arranged externally to an airway in a generally helical pattern with pitch angles ranging from about ⁇ 30 to about +30 degrees.
- the treatment of the smooth muscle which may be selectively given in an appropriate pattern, interrupts or cuts through the helical pattern at a proper pitch and prevents the airway from constricting. Therefore, a variation of the invention may include treating the airway smooth muscle in one or more sites or in a pattern to eliminates contraction of the airways without completely eradicating smooth muscle and other airway tissue.
- a variation of the invention includes treating at one or a few sites to inactivate all or a significant portion of the airway smooth muscle.
- FIGS. 1 and 2 illustrate cross sections of an airway and a bronchiole, respectively, in a healthy patient.
- the airway of FIG. 1 is a medium sized bronchus having an airway diameter D1 of about 3 mm.
- FIG. 2 shows a section through a bronchiole having an airway diameter D2 of about 1.5 mm.
- Each airway includes a folded inner surface or epithelium 10 surrounded by stroma 12 and smooth muscle tissue 14 .
- the larger airways including the bronchus shown in FIG. 1 also have mucous glands 16 and cartilage 18 surrounding the smooth muscle tissue 14 . Nerve fibers 20 and blood vessels 22 also surround the airway.
- FIG. 3 illustrates, the bronchus of FIG. 1 in which the smooth muscle 14 hypertrophied and increased in thickness causing the airway diameter to be reduced from the diameter D1 to a diameter D3.
- the smooth muscle tissue 14 is responsible for constriction of the airways.
- the adverse affects of excessive airway constriction may be alleviated by directly inactivating or deactivating the function of the airway smooth muscle.
- the airway smooth muscle relies upon the bronchial vasculature for its blood supply. Therefore, any altering of the blood supply in the bronchial system significantly affects the airway smooth muscle as compared to the remaining airway wall or bronchial tissue. Because of this, the airway smooth muscle's blood supply may be treated so that the effects of the treatment are acceptably limited to the airway smooth muscle. Furthermore, the blood-air exchange function of the alveoli (the most distal portion of the airway that provides a gas exchange function), relies upon a separate vasculature network. So any actions taken on the bronchial vasculature may be controlled so that they will have little or no effect upon the remaining circulatory system, including the pulmonary vasculature.
- FIG. 4 is a representative illustration of the lungs 2 , airways 4 , pulmonary arteries 6 , pulmonary veins 8 , and bronchial veins and arteries 22 .
- a treatment location is selected.
- the bronchial arteries 24 run within the airway wall. It is noted that the location or treatment site may be selected either from sensing within the airway 4 (e.g., via Doppler sensing), external means by any mode of non-invasive detection, and/or by any other means of locating an acceptable site to provide the treatment.
- FIG. 4 also illustrates a variation of the treatment where a catheter 40 advances into the airways.
- the catheter 40 may be equipped to perform the procedure as discussed herein. By advancing the catheter 40 through the airways, the treatment may be delivered to the bronchial artery without having to puncture the pleura.
- FIG. 5 shows a representation of an airway 4 terminating into the alveolus 3 .
- the airway 4 includes a bronchial artery 6 and a bronchial vein 8 running exterior to the lumen of the airway.
- the bronchial arteries and veins 24 and 26 run externally along either side of the main bronchus and follow the branching of the airways 4 .
- the location of the bronchial artery 24 allows for any number of modes of detection (e.g., Doppler, thermal, etc.) to locate a possible treatment site.
- the treatment described herein may be provided via a minimally invasive approach.
- a medical practitioner advances a treatment device 40 (e.g., a bronchoscope carrying a catheter, a catheter, etc.) into the airways 4 .
- the medical practitioner may apply the treatment from outside the body through injection, or even oral administration.
- Some variations of the treatment described herein allow for treatment of the airway smooth muscle tissue, which is located in a considerable number of airways, could be applied in a single or relatively few locations (e.g., one or more sites in the bronchial arteries.) This advantage allows for treatment at relatively few sites as opposed to having to treat the entire (or considerable portion) of the bronchial network.
- the medical practitioner injects an agent into the bronchial artery or arteries 24 supplying the airways 4 .
- the agent affects the blood supplied to the smooth muscle tissue within the airway.
- the agent reaches the smooth muscle tissue to deactivate, or impair the function of the smooth muscle tissue.
- the inability of the smooth muscle tissue to constrict the airways improves the breathing condition of the patent (e.g., in cases of an asthma attack.)
- the agents described herein may include toxins, radioactive agents, viral agents, and/or drugs.
- Example of such agents includes toxins such as natural, animal or insect toxins, or engineered toxins, I-131 (Iodine 131), laser absorptive dye, agents that bind to constituents of airway smooth muscle (e.g., myosin, actin), neutrophils, paralytic agents, embolizing agents, etc.
- agents that selectively affect smooth muscle tissue include: snake myotoxins; anti-bodies that bind to actin or myosin, with the impairment agent bound to the antibody.
- the agent may also include microspheres the size of the capillaries at the smooth muscle. These micropspheres could also contain an additional agent.
- a variation of the treatment may include delivering a second agent which counteracts the effect of the first agent.
- the second agent is provided so that the treatment is limited to the. desired part of the body (e.g., the airways.)
- a counteracting agent may be introduced systemically or locally but in a way so that the initial treatment is not rendered ineffective.
- the agent is cyanide the counteragent or protectant agent could be amyl nitrate Accordingly, as the agent affect the smooth muscle in the airways, the counteracting agent minimizes adverse effect on other smooth muscle that is not a subject of the treatment.
- counteragents examples include, but is not limited to, antivenom. It is also contemplated that instead of a counter-agent, a mechanical filter or binding substance may be used to ‘collect’ or deactivate the agent before the agent is able to affect non-target tissues. Furthermore, a counteractive measure may be applied to the same effect as a counter agent. For example, an agent may be applied where the agent may be rendered ineffective under certain environments (e.g., upon the application of current, an electric field, or other chemical reaction.)
- the counteragent may be provided in such a way that it allows for “dosing” of the agent.
- the agent may be applied in a concentration strong enough to have the desired effect, but through dilution, degradation, or through systemic counteragent (at a dose that cannot protect the targeted tissues which see a “too strong” dose of agent) cannot affect other organ systems.
- a variation of the treatment described herein includes ligating or reducing flow within the bronchial vessel or vessels so that the agent is trapped or delayed in the desired treatment location until a significant amount of the agent is absorbed or until the agent decays or is rendered inactive.
- a radioactive agent with a properly selected half-life may be used.
- reducing the flow of the agent trapping the agent within the bronchial vessels may allow a sufficient amount of time to pass so that the radioactive agent decays sufficiently so that any of the agent that passes to other portions of the body is rendered sufficiently ineffective to cause any concern of side effects.
- This approach of reducing the blood flow may be accomplished at the arterial side of the flow (i.e, the inflow side), and/or may be accomplished at the venous side of the flow (i.e., the outflow side).
- the blood supply to the target smooth muscle may be interrupted or reduced to starve the smooth muscle by reducing oxygen supply to the muscle to induce temporary or permanent deactivation of the muscle.
- the blood supply may be altered by introducing an agent that occludes blood flow in the vessel.
- the blood vessels may be starved of necessary nutrients or otherwise induced to create damaging toxins on their own.
- the occluding agent could be any agent, combination of agents and/or devices that restricts blood flow.
- the blood supply may be altered by simply damaging the blood vessel or shunting blood flow to a different region so that blood does not reach the targeted smooth muscle tissue.
- the bronchial artery may be coagulated to stop flow.
- the blood flow in the bronchial artery may be shunted to the pulmonary vessels or the bronchial vein.
- the bronchial vein may also be closed to accomplish the appropriate result of affecting the smooth muscle tissue.
- the treatment described herein may be combined with other conventional treatments.
- the treatments herein may be combined with stimulus avoidance or pharmacological management of asthma.
- the treatments may be combined with the treatments described in the following commonly assigned patents and applications.
- U.S. Published application 20030233099A1; 20040010289A1; 20020091379A1.
- U.S. Pat. Nos. 6,411,852; 6,634,363 the entirety of all of which are incorporated by reference herein so that they may be combined with the inventive procedures and treatments described herein.
- the smooth muscle may be stimulated during treatment to increase its demand for oxygen from the blood system.
- the increased demand for oxygen may cause, either more of the agent to pass to the target smooth muscle, or in cases where the blood flow is interrupted, the lack of oxygen causes ischemia of the “activated” smooth muscle at an increased rate.
- the effectiveness of the treatments and procedures described herein may be titrated.
- the treatment may be performed under stimulated constriction of the airways.
- a medical practitioner would then observe the effects of the treatment (either real time and/or under direct observation, or through other measurement modes). Upon reaching the desired effect, the medical practitioner would stop the treatment.
- methocholine which stimulates smooth muscle activity
- the smooth muscle may be stimulated electrically, or by other stimulus.
- the treatments and/or agents described herein may also be combined with temperature, dyes, or other detectible additives.
- blood on the arterial side of the airway smooth muscle may be heated or cooled (alternatively, it may be the agent that is heated or cooled.)
- one variation of the invention includes cooling the agent, injecting the agent into the blood flow, then measuring the temperature of the vein or venous flow. A drop in temperature (or observation of the additive) at this location informs the medical practitioner that the agent or altered blood passed through the smooth muscle.
Abstract
Treatment and procedures for treating bodily conduits involves deactivating, killing, or otherwise treating smooth muscle tissue of the conduit.
Description
- This is a non-provisional of U.S. Provisional Application Ser. No. 60/610,925 filed Aug. 18, 2004, the entirety of which is incorporated by reference.
- Asthma is a serious chronic condition. In the United States alone, it is believed that asthma affects upward of 15 million Americans. Asthma is characterized by (i) bronchoconstriction, (ii) excessive mucus production, and (iii) inflammation and swelling of airways. These conditions cause widespread and variable airflow obstruction thereby making it difficult for the asthma sufferer to breathe. Asthma further includes acute episodes or attacks of additional airway narrowing via contraction of hyper-responsive airway smooth muscle. Other obstructive diseases such as COPD may also have a reversible component caused by one or more of the above mentioned three elements.
- Asthma generally includes excessive mucus production in the bronchial tree. Usually, there is a general increase in bulk (hypertrophy) of the large bronchi and chronic inflammatory changes in the small airways. See for example, Hogg, J C. The Pathology of Asthma. APMIS 1997; 105:735-745. Excessive amounts of mucus are found in the airways and semisolid plugs of mucus may occlude some small bronchi. Also, the small airways are narrowed and may show inflammatory changes. See, e.g., Kraft M, The Distal Airways: Are they Important in Asthma? Eur Respir J 1999; 14:1403-1417. The reversible aspects of COPD include partial airway occlusion by excess secretions, bronchial wall edema, inflammation of the airways and airway narrowing as a result of smooth muscle contraction.
- The role of airway smooth muscle and its effect in patients with asthma is gaining increased attention in the medical community. See, for example, Shore S, Airway Smooth Muscle in Asthma—Not Just More of the Same, 2004 N Engl J Med 351; 6; Jeffery P K. Remodeling in Asthma and Chronic Obstructive Lung Diseas., Am J. Respir Crit Care Med 2001; 1645: S28-S38; Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention, NIH/NHLBI, 2002 NIH Publication No 02-3659 Furthermore, the literature tends to support the belief that smooth muscle tissue within the airways is not essential to normal lung physiology and that the smooth muscle tissue may in fact be a vestigial organ. In the case of individuals with asthma, the airway smooth muscle may actually cause medical complications. See, for example, Seow C Y, Fredberg J J, Historical Perspective on Airway Smooth Muscle: the Saga of a Frustrated Cell, 2001 Appl Physiol 91(2):938-952, Mitzner W, Airway Smooth Muscle: the Appendix of the Lung, 2004 AJRCCM, 169:787-790.
- Currently, asthma management includes a combination of stimulus avoidance and pharmacological mediation. Stimulus avoidance includes systematic identification of each type of stimuli and minimization of contact with each type of stimuli. It may, however, be impractical and not always helpful to avoid all potential stimuli.
- Pharmacological mediation of asthma includes: (1) long term control through use of anti-inflammatories and long-acting bronchodilators and (2) short term management of acute exacerbations through use of short-acting bronchodilators. Both approaches require repeated and regular use of the prescribed drugs. High doses of corticosteroid anti-inflammatory drugs may include serious side effects requiring careful management. In addition, some patients are resistant to steroid treatment.
- The difficulties involved in patient compliance with pharmacologic management and the difficulties of avoiding asthma triggering stimulus are common barriers to successful asthma management. It follows that current management techniques are neither completely successful nor free from side effects. Aside from the difficulties in these management techniques, some individuals may seek a more permanent solution to manage asthma.
- Removal and/or deactivation of a body organ, vestigial or not, is medically acceptable as long as there is an overall benefit. A few examples of such procedures include removal of: body hair, the appendix, wisdom teeth, and portions of the cornea. Moreover, deactivation of certain muscles is accepted for cosmetic results. In this latter procedure, a physician injects botulism toxin type A (i.e., BOTOX®) directly into the corrugator and procerus muscles, preventing them from contracting and eventually causing the skin to become smoother,
- Additionally, use of RF energy when applied to the airways has been shown to decrease the ability of smooth muscle tissue to narrow the airways. Danek C J, et al, Reduction in Airway Hyperresponsiveness to Methacholine by the Application of RF Energy in Dogs. 2004 J Appl Physiol. Jul. 16 doi:10.1152/japplphysiol.01282.2003 (electronic publication—ahead of print)
- In view of the foregoing, there remains an additional need for removal and/or deactivation of certain types of muscle which may contribute to or cause an impaired quality of life. In just one specific example, there remains a need to remove and/or deactivate certain airway smooth muscle to address the effects of certain pulmonary conditions, including but not limited to asthma.
- The present invention includes methods of treating smooth muscle tissue to prevent adverse effects resulting from constriction of body passages. Though the approaches discussed below discuss treatment of airway smooth muscle to prevent bronchoconstriction in cases of pulmonary disorders, it is contemplated that variations of the treatment are not limited to airway smooth muscle. Variations of the treatments and procedures described herein may be applied to non-airway smooth muscle where appropriate.
- The treatments and procedures described below include methods of treating individual for hyper-responsiveness of a body passage, where the method comprises placing an agent into a blood vessel that supplies blood to tissue of the body passage, where the agent affects'the ability of the body passage to constrict.
- Also disclosed are methods of reducing the ability of a body passage to constrict in response to stimulus, where the method comprises altering a blood supply of smooth muscle tissue in the body passage to lessen or eliminate the ability of a portion of the smooth muscle tissue to constrict the body passage. In this case altering blood flow may include adding an agent to the blood that affects smooth muscle as discussed herein. Alternatively, or in combination, altering of the blood flow may comprise slowing or stopping the flow of blood to the target smooth muscle to affect the smooth muscle tissue.
- The agents described herein may include toxins, radioactive agents, viral agents, and/or drugs. Example of such agents includes toxins such as natural, animal or insect toxins, or engineered toxins; I-131 (Iodine 131), laser absorptive dye, agents that bind to constituents of airway smooth muscle (e.g., myosin, actin), neutrophils, paralytic agents, embolizing agents, etc. Examples of agents that selectively affect smooth muscle tissue include: snake myotoxins; anti-bodies that bind to actin or myosin, with the impairment agent bound to the antibody. The agent may also include microspheres the size of the capillaries at the smooth muscle. These micropspheres could also contain an additional agent.
- Variations of the invention described herein include procedures and treatments that deliver a persistent treatment to prevent the ability of body passages to constrict.
-
FIG. 1 is a cross sectional view of an airway in a healthy lung. -
FIG. 2 shows a section through a bronchiole having an airway diameter smaller than that shown inFIG. 1 . -
FIG. 3 illustrates an airway similar to that ofFIG. 1 but in which the smooth muscle hypertrophied and increased in thickness causing reduction of the airway diameter. -
FIG. 4 is a representation of the lungs, airway, pulmonary vessels and bronchial vessels. -
FIG. 5 is a representation of the bronchial artery and vein as it runs along an airway. - The invention relates to reducing or preventing a body passage from constricting by inactivating or therapeutically damaging the smooth muscle which causes contraction of the body passage. Although the invention described herein may have applications throughout the body, the variation of the invention described below relates to treating airway smooth muscle tissue to prevent or reduce constriction of the airways within a lung. As noted above, preventing or reducing constriction of the airways allows for improved breathing for individual suffering from a pulmonary condition, such as asthma.
- The inventive treatment reduces the ability of the airways to constrict, narrow or to reduce in diameter due to airway smooth muscle contraction. The reduction in the ability of the smooth muscle to contract may lie achieved by treating the smooth muscle itself or by treating other tissues to affect smooth muscle contraction or the response of the airway to the smooth muscle contraction. Treatment may also reduce airway responsiveness or the tendency of the airway, to narrow or to constrict in response to a stimulus.
- The reduction in smooth muscle and surrounding tissue may also have the added potential benefit of increasing the caliber or diameter of the airways, this benefit reduces the resistance to airflow through the airways. In addition to the use of debulking smooth muscle tissue to open up the airways, the devices and/or approach of the present invention may eliminate smooth muscle altogether by damaging or destroying the muscle.
- In the airways, the smooth muscle is arranged externally to an airway in a generally helical pattern with pitch angles ranging from about −30 to about +30 degrees. Thus, the treatment of the smooth muscle, which may be selectively given in an appropriate pattern, interrupts or cuts through the helical pattern at a proper pitch and prevents the airway from constricting. Therefore, a variation of the invention may include treating the airway smooth muscle in one or more sites or in a pattern to eliminates contraction of the airways without completely eradicating smooth muscle and other airway tissue. Alternatively, a variation of the invention includes treating at one or a few sites to inactivate all or a significant portion of the airway smooth muscle.
-
FIGS. 1 and 2 illustrate cross sections of an airway and a bronchiole, respectively, in a healthy patient. The airway ofFIG. 1 is a medium sized bronchus having an airway diameter D1 of about 3 mm.FIG. 2 shows a section through a bronchiole having an airway diameter D2 of about 1.5 mm. Each airway includes a folded inner surface orepithelium 10 surrounded bystroma 12 andsmooth muscle tissue 14. The larger airways including the bronchus shown inFIG. 1 also havemucous glands 16 andcartilage 18 surrounding thesmooth muscle tissue 14.Nerve fibers 20 andblood vessels 22 also surround the airway. -
FIG. 3 illustrates, the bronchus ofFIG. 1 in which thesmooth muscle 14 hypertrophied and increased in thickness causing the airway diameter to be reduced from the diameter D1 to a diameter D3. - In any case, the
smooth muscle tissue 14 is responsible for constriction of the airways. As noted herein, the adverse affects of excessive airway constriction may be alleviated by directly inactivating or deactivating the function of the airway smooth muscle. - The airway smooth muscle relies upon the bronchial vasculature for its blood supply. Therefore, any altering of the blood supply in the bronchial system significantly affects the airway smooth muscle as compared to the remaining airway wall or bronchial tissue. Because of this, the airway smooth muscle's blood supply may be treated so that the effects of the treatment are acceptably limited to the airway smooth muscle. Furthermore, the blood-air exchange function of the alveoli (the most distal portion of the airway that provides a gas exchange function), relies upon a separate vasculature network. So any actions taken on the bronchial vasculature may be controlled so that they will have little or no effect upon the remaining circulatory system, including the pulmonary vasculature.
-
FIG. 4 is a representative illustration of thelungs 2,airways 4,pulmonary arteries 6,pulmonary veins 8, and bronchial veins andarteries 22. To deliver the treatment in accordance with the teachings described herein, a treatment location is selected. Generally, the bronchial arteries 24 run within the airway wall. It is noted that the location or treatment site may be selected either from sensing within the airway 4 (e.g., via Doppler sensing), external means by any mode of non-invasive detection, and/or by any other means of locating an acceptable site to provide the treatment. -
FIG. 4 also illustrates a variation of the treatment where acatheter 40 advances into the airways. Thecatheter 40 may be equipped to perform the procedure as discussed herein. By advancing thecatheter 40 through the airways, the treatment may be delivered to the bronchial artery without having to puncture the pleura. -
FIG. 5 shows a representation of anairway 4 terminating into thealveolus 3. As shown, theairway 4, includes abronchial artery 6 and abronchial vein 8 running exterior to the lumen of the airway. As illustrated, the bronchial arteries and veins 24 and 26 run externally along either side of the main bronchus and follow the branching of theairways 4. The location of the bronchial artery 24 allows for any number of modes of detection (e.g., Doppler, thermal, etc.) to locate a possible treatment site. - The treatment described herein may be provided via a minimally invasive approach. For example, a medical practitioner advances a treatment device 40 (e.g., a bronchoscope carrying a catheter, a catheter, etc.) into the
airways 4. Alternatively, or in combination, the medical practitioner may apply the treatment from outside the body through injection, or even oral administration. Some variations of the treatment described herein allow for treatment of the airway smooth muscle tissue, which is located in a considerable number of airways, could be applied in a single or relatively few locations (e.g., one or more sites in the bronchial arteries.) This advantage allows for treatment at relatively few sites as opposed to having to treat the entire (or considerable portion) of the bronchial network. - In one variation of the treatment, the medical practitioner injects an agent into the bronchial artery or arteries 24 supplying the
airways 4. As noted above, the agent affects the blood supplied to the smooth muscle tissue within the airway. In turn, the agent reaches the smooth muscle tissue to deactivate, or impair the function of the smooth muscle tissue. As a result, the inability of the smooth muscle tissue to constrict the airways improves the breathing condition of the patent (e.g., in cases of an asthma attack.) - The agents described herein may include toxins, radioactive agents, viral agents, and/or drugs. Example of such agents includes toxins such as natural, animal or insect toxins, or engineered toxins, I-131 (Iodine 131), laser absorptive dye, agents that bind to constituents of airway smooth muscle (e.g., myosin, actin), neutrophils, paralytic agents, embolizing agents, etc. Examples of agents that selectively affect smooth muscle tissue include: snake myotoxins; anti-bodies that bind to actin or myosin, with the impairment agent bound to the antibody. The agent may also include microspheres the size of the capillaries at the smooth muscle. These micropspheres could also contain an additional agent.
- A variation of the treatment may include delivering a second agent which counteracts the effect of the first agent. In such a case, the second agent is provided so that the treatment is limited to the. desired part of the body (e.g., the airways.) For example, if a toxin is applied to the bronchial artery, a counteracting agent may be introduced systemically or locally but in a way so that the initial treatment is not rendered ineffective. For example, if the agent is cyanide the counteragent or protectant agent could be amyl nitrate Accordingly, as the agent affect the smooth muscle in the airways, the counteracting agent minimizes adverse effect on other smooth muscle that is not a subject of the treatment. Examples of such counteragents include, but is not limited to, antivenom. It is also contemplated that instead of a counter-agent, a mechanical filter or binding substance may be used to ‘collect’ or deactivate the agent before the agent is able to affect non-target tissues. Furthermore, a counteractive measure may be applied to the same effect as a counter agent. For example, an agent may be applied where the agent may be rendered ineffective under certain environments (e.g., upon the application of current, an electric field, or other chemical reaction.)
- The counteragent may be provided in such a way that it allows for “dosing” of the agent. For example, the agent may be applied in a concentration strong enough to have the desired effect, but through dilution, degradation, or through systemic counteragent (at a dose that cannot protect the targeted tissues which see a “too strong” dose of agent) cannot affect other organ systems.
- A variation of the treatment described herein includes ligating or reducing flow within the bronchial vessel or vessels so that the agent is trapped or delayed in the desired treatment location until a significant amount of the agent is absorbed or until the agent decays or is rendered inactive. For example, a radioactive agent with a properly selected half-life may be used. In this case, reducing the flow of the agent trapping the agent within the bronchial vessels may allow a sufficient amount of time to pass so that the radioactive agent decays sufficiently so that any of the agent that passes to other portions of the body is rendered sufficiently ineffective to cause any concern of side effects. This approach of reducing the blood flow may be accomplished at the arterial side of the flow (i.e,, the inflow side), and/or may be accomplished at the venous side of the flow (i.e., the outflow side).
- In another example of the inventive treatment, the blood supply to the target smooth muscle may be interrupted or reduced to starve the smooth muscle by reducing oxygen supply to the muscle to induce temporary or permanent deactivation of the muscle. In this variation of the treatment, the blood supply may be altered by introducing an agent that occludes blood flow in the vessel. In some cases, the blood vessels may be starved of necessary nutrients or otherwise induced to create damaging toxins on their own. The occluding agent could be any agent, combination of agents and/or devices that restricts blood flow.
- Alternatively, or in addition, the blood supply may be altered by simply damaging the blood vessel or shunting blood flow to a different region so that blood does not reach the targeted smooth muscle tissue. For example, the bronchial artery may be coagulated to stop flow. In another variation, the blood flow in the bronchial artery may be shunted to the pulmonary vessels or the bronchial vein. The bronchial vein may also be closed to accomplish the appropriate result of affecting the smooth muscle tissue.
- The treatment described herein may be combined with other conventional treatments. For example, for asthma management, the treatments herein may be combined with stimulus avoidance or pharmacological management of asthma. In addition, the treatments may be combined with the treatments described in the following commonly assigned patents and applications. U.S. patent application Ser. No. 09/095,323 filed Jun. 10, 1998; Ser. No. 09/436,455 filed Nov. 8, 1999. U.S. Published application: 20030233099A1; 20040010289A1; 20020091379A1. U.S. Pat. Nos. 6,411,852; 6,634,363 the entirety of all of which are incorporated by reference herein so that they may be combined with the inventive procedures and treatments described herein.
- The effectiveness of the treatments and procedures described above may be further improved through exercise or activation of the target smooth muscle while the treatment or procedure is in process. For example, the smooth muscle may be stimulated during treatment to increase its demand for oxygen from the blood system. In turn, the increased demand for oxygen may cause, either more of the agent to pass to the target smooth muscle, or in cases where the blood flow is interrupted, the lack of oxygen causes ischemia of the “activated” smooth muscle at an increased rate.
- In addition, the effectiveness of the treatments and procedures described herein may be titrated. In this case, the treatment may be performed under stimulated constriction of the airways. A medical practitioner would then observe the effects of the treatment (either real time and/or under direct observation, or through other measurement modes). Upon reaching the desired effect, the medical practitioner would stop the treatment. For example, methocholine, which stimulates smooth muscle activity, may be placed in the airway to stimulate the smooth muscle. Alternatively, or in combination, the smooth muscle may be stimulated electrically, or by other stimulus.
- The treatments and/or agents described herein may also be combined with temperature, dyes, or other detectible additives. For example, blood on the arterial side of the airway smooth muscle may be heated or cooled (alternatively, it may be the agent that is heated or cooled.) Then, by measuring the blood flow on the venous side of the airway smooth muscle, one is able to confirm when the agent or effect has passed through the smooth muscle. For example, one variation of the invention includes cooling the agent, injecting the agent into the blood flow, then measuring the temperature of the vein or venous flow. A drop in temperature (or observation of the additive) at this location informs the medical practitioner that the agent or altered blood passed through the smooth muscle.
- While the invention has been described in detail with reference to the preferred embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made and equivalents employed, without departing from the present invention. Furthermore, the above illustrations and descriptions are examples of a number of non-exhaustive variations the invention described herein. It is contemplated that combinations of aspects of specific embodiments or combinations of the specific embodiments themselves are within the scope of this disclosure.
Claims (21)
1. A method of reducing the ability of a lung airway to narrow, the method comprising:
placing an effective amount of a muscle impairing agent into a blood vessel that supplies blood to tissue of the lung airway, where the muscle impairing agent affects the ability of the lung airway to constrict in response to a stimulus.
2-47. (canceled)
48. The method of claim 1 , wherein the blood vessel comprises a bronchial artery.
49. The method of claim 1 , wherein the agent includes one or more of an artificial toxin, a naturally occurring toxin, a radioactive agent, a viral agent, a drug, Iodine 131, laser absorptive dyes, an agent that binds to constituents of airway smooth muscle, neutrophils, paralytic agents, and embolizing agents.
50. The method of claim 1 , further comprising delivering a second agent to the body, wherein the second agent protects a portion of the body against the effects of the agent.
51. The method of claim 50 , wherein the second agent is delivered by a mode selected from the group consisting of inhalation, injection, and oral administration.
52. The method of claim 1 , further comprising stimulating the lung airway.
53. The method of claim 52 , wherein stimulating the lung airway increases absorption of the agent.
54. The method of claim 52 , wherein placing the agent comprises injecting the agent in response to an amount of contraction of the airway caused by the stimulation.
55. The method of claim 1 , further comprising selecting a second vascular site, and reducing blood flow in the second vascular site to decrease the flow rate of the agent in the blood vessel.
56. The method of claim 1 , further comprising monitoring the blood to determine an amount of the agent in the blood.
57. A method of reducing the ability of a lung airway to narrow, the method comprising:
placing an effective amount of an agent into a blood vessel that supplies blood to smooth muscle tissue of a lung such that the agent reaches the smooth muscle tissue, wherein the agent affects the smooth muscle tissue, reducing the ability of the lung airway to constrict in response to a stimulus.
58. The method of claim 57 , wherein the agent impairs, deactivates, or kills the smooth muscle tissue.
59. The method of claim 57 , wherein the blood vessel comprises a bronchial artery.
60. The method of claim 57 , wherein the agent includes one or more of an artificial toxin, a naturally occurring toxin, a radioactive agent, a viral agent, a drug, Iodine 131, laser absorptive dyes, an agent that binds to constituents of airway smooth muscle, neutrophils, paralytic agents, and embolizing agents.
61. The method of claim 60 , further comprising delivering a second agent to the body, wherein the second agent protects a portion of the body against the effects of the agent.
62. The method of claim 61 , wherein the second agent is delivered by a mode selected from the group consisting of inhalation, injection, and oral administration.
63. The method of claim 57 , further comprising stimulating the lung airway.
64. The method of claim 63 , wherein stimulating the lung airway increases absorption of the agent.
65. The method of claim 63 , wherein placing the agent comprises injecting the agent in response to an amount of contraction of the airway caused by the stimulation.
66. The method of claim 57 , further comprising selecting a second vascular site, and reducing blood flow in the second vascular site to decrease the flow rate of the agent in the blood vessel.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/447,098 US20140341801A1 (en) | 2004-09-18 | 2014-07-30 | Inactivation of smooth muscle tissue |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61092504P | 2004-09-18 | 2004-09-18 | |
US10/954,895 US7906124B2 (en) | 2004-09-18 | 2004-09-30 | Inactivation of smooth muscle tissue |
US13/018,713 US8828945B2 (en) | 2004-09-18 | 2011-02-01 | Inactivation of smooth muscle tissue |
US14/447,098 US20140341801A1 (en) | 2004-09-18 | 2014-07-30 | Inactivation of smooth muscle tissue |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/018,713 Continuation US8828945B2 (en) | 2004-09-18 | 2011-02-01 | Inactivation of smooth muscle tissue |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140341801A1 true US20140341801A1 (en) | 2014-11-20 |
Family
ID=36074277
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/954,895 Active 2027-06-02 US7906124B2 (en) | 2004-09-18 | 2004-09-30 | Inactivation of smooth muscle tissue |
US13/018,713 Active 2026-11-13 US8828945B2 (en) | 2004-09-18 | 2011-02-01 | Inactivation of smooth muscle tissue |
US14/447,098 Abandoned US20140341801A1 (en) | 2004-09-18 | 2014-07-30 | Inactivation of smooth muscle tissue |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/954,895 Active 2027-06-02 US7906124B2 (en) | 2004-09-18 | 2004-09-30 | Inactivation of smooth muscle tissue |
US13/018,713 Active 2026-11-13 US8828945B2 (en) | 2004-09-18 | 2011-02-01 | Inactivation of smooth muscle tissue |
Country Status (1)
Country | Link |
---|---|
US (3) | US7906124B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10702337B2 (en) | 2016-06-27 | 2020-07-07 | Galary, Inc. | Methods, apparatuses, and systems for the treatment of pulmonary disorders |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7425212B1 (en) * | 1998-06-10 | 2008-09-16 | Asthmatx, Inc. | Devices for modification of airways by transfer of energy |
US7027869B2 (en) * | 1998-01-07 | 2006-04-11 | Asthmatx, Inc. | Method for treating an asthma attack |
US6634363B1 (en) | 1997-04-07 | 2003-10-21 | Broncus Technologies, Inc. | Methods of treating lungs having reversible obstructive pulmonary disease |
US7992572B2 (en) | 1998-06-10 | 2011-08-09 | Asthmatx, Inc. | Methods of evaluating individuals having reversible obstructive pulmonary disease |
US6488673B1 (en) * | 1997-04-07 | 2002-12-03 | Broncus Technologies, Inc. | Method of increasing gas exchange of a lung |
US7921855B2 (en) | 1998-01-07 | 2011-04-12 | Asthmatx, Inc. | Method for treating an asthma attack |
US7198635B2 (en) | 2000-10-17 | 2007-04-03 | Asthmatx, Inc. | Modification of airways by application of energy |
US8181656B2 (en) | 1998-06-10 | 2012-05-22 | Asthmatx, Inc. | Methods for treating airways |
US20070123958A1 (en) * | 1998-06-10 | 2007-05-31 | Asthmatx, Inc. | Apparatus for treating airways in the lung |
US8251070B2 (en) | 2000-03-27 | 2012-08-28 | Asthmatx, Inc. | Methods for treating airways |
US7104987B2 (en) | 2000-10-17 | 2006-09-12 | Asthmatx, Inc. | Control system and process for application of energy to airway walls and other mediums |
US20040226556A1 (en) * | 2003-05-13 | 2004-11-18 | Deem Mark E. | Apparatus for treating asthma using neurotoxin |
US7906124B2 (en) * | 2004-09-18 | 2011-03-15 | Asthmatx, Inc. | Inactivation of smooth muscle tissue |
US7949407B2 (en) | 2004-11-05 | 2011-05-24 | Asthmatx, Inc. | Energy delivery devices and methods |
WO2006052940A2 (en) * | 2004-11-05 | 2006-05-18 | Asthmatx, Inc. | Medical device with procedure improvement features |
US20070093802A1 (en) * | 2005-10-21 | 2007-04-26 | Danek Christopher J | Energy delivery devices and methods |
JP5020824B2 (en) * | 2004-11-16 | 2012-09-05 | ロバート・エル・バリー | Lung therapy apparatus and method |
WO2006116198A2 (en) * | 2005-04-21 | 2006-11-02 | Asthmatx, Inc. | Control methods and devices for energy delivery |
US7931647B2 (en) * | 2006-10-20 | 2011-04-26 | Asthmatx, Inc. | Method of delivering energy to a lung airway using markers |
US7993323B2 (en) | 2006-11-13 | 2011-08-09 | Uptake Medical Corp. | High pressure and high temperature vapor catheters and systems |
US8235983B2 (en) | 2007-07-12 | 2012-08-07 | Asthmatx, Inc. | Systems and methods for delivering energy to passageways in a patient |
US20090043301A1 (en) * | 2007-08-09 | 2009-02-12 | Asthmatx, Inc. | Monopolar energy delivery devices and methods for controlling current density in tissue |
US8322335B2 (en) | 2007-10-22 | 2012-12-04 | Uptake Medical Corp. | Determining patient-specific vapor treatment and delivery parameters |
US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
EP2529686B1 (en) | 2008-05-09 | 2015-10-14 | Holaira, Inc. | System for treating a bronchial tree |
US9649153B2 (en) | 2009-10-27 | 2017-05-16 | Holaira, Inc. | Delivery devices with coolable energy emitting assemblies |
CA2780608C (en) | 2009-11-11 | 2019-02-26 | Innovative Pulmonary Solutions, Inc. | Systems, apparatuses, and methods for treating tissue and controlling stenosis |
US8911439B2 (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
EP2854682B1 (en) | 2012-06-04 | 2021-06-23 | Boston Scientific Scimed, Inc. | Systems for treating tissue of a passageway within a body |
EP2877113B1 (en) | 2012-07-24 | 2018-07-25 | Boston Scientific Scimed, Inc. | Electrodes for tissue treatment |
US9272132B2 (en) | 2012-11-02 | 2016-03-01 | Boston Scientific Scimed, Inc. | Medical device for treating airways and related methods of use |
WO2014071372A1 (en) | 2012-11-05 | 2014-05-08 | Boston Scientific Scimed, Inc. | Devices for delivering energy to body lumens |
US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
US9814618B2 (en) | 2013-06-06 | 2017-11-14 | Boston Scientific Scimed, Inc. | Devices for delivering energy and related methods of use |
EP3030182B1 (en) | 2013-08-09 | 2018-01-10 | Boston Scientific Scimed, Inc. | Expandable catheter |
US9782211B2 (en) | 2013-10-01 | 2017-10-10 | Uptake Medical Technology Inc. | Preferential volume reduction of diseased segments of a heterogeneous lobe |
US10485604B2 (en) | 2014-12-02 | 2019-11-26 | Uptake Medical Technology Inc. | Vapor treatment of lung nodules and tumors |
US10531906B2 (en) | 2015-02-02 | 2020-01-14 | Uptake Medical Technology Inc. | Medical vapor generator |
US11129673B2 (en) | 2017-05-05 | 2021-09-28 | Uptake Medical Technology Inc. | Extra-airway vapor ablation for treating airway constriction in patients with asthma and COPD |
US11344364B2 (en) | 2017-09-07 | 2022-05-31 | Uptake Medical Technology Inc. | Screening method for a target nerve to ablate for the treatment of inflammatory lung disease |
US11350988B2 (en) | 2017-09-11 | 2022-06-07 | Uptake Medical Technology Inc. | Bronchoscopic multimodality lung tumor treatment |
USD845467S1 (en) | 2017-09-17 | 2019-04-09 | Uptake Medical Technology Inc. | Hand-piece for medical ablation catheter |
US11419658B2 (en) | 2017-11-06 | 2022-08-23 | Uptake Medical Technology Inc. | Method for treating emphysema with condensable thermal vapor |
US11490946B2 (en) | 2017-12-13 | 2022-11-08 | Uptake Medical Technology Inc. | Vapor ablation handpiece |
US11653927B2 (en) | 2019-02-18 | 2023-05-23 | Uptake Medical Technology Inc. | Vapor ablation treatment of obstructive lung disease |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303145B2 (en) * | 1999-05-10 | 2001-10-16 | Sepracor Inc. | (S,R) formoterol methods and compositions |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
US5807308A (en) | 1996-02-23 | 1998-09-15 | Somnus Medical Technologies, Inc. | Method and apparatus for treatment of air way obstructions |
JPH0947518A (en) | 1995-06-26 | 1997-02-18 | Lederle Japan Ltd | Optical fiber laser probe for photodynamic therapy |
US6743197B1 (en) | 1996-07-10 | 2004-06-01 | Novasys Medical, Inc. | Treatment of discrete tissues in respiratory, urinary, circulatory, reproductive and digestive systems |
US6488673B1 (en) | 1997-04-07 | 2002-12-03 | Broncus Technologies, Inc. | Method of increasing gas exchange of a lung |
US6273907B1 (en) | 1997-04-07 | 2001-08-14 | Broncus Technologies, Inc. | Bronchial stenter |
US6634363B1 (en) | 1997-04-07 | 2003-10-21 | Broncus Technologies, Inc. | Methods of treating lungs having reversible obstructive pulmonary disease |
US5972026A (en) | 1997-04-07 | 1999-10-26 | Broncus Technologies, Inc. | Bronchial stenter having diametrically adjustable electrodes |
US7992572B2 (en) | 1998-06-10 | 2011-08-09 | Asthmatx, Inc. | Methods of evaluating individuals having reversible obstructive pulmonary disease |
US6083255A (en) | 1997-04-07 | 2000-07-04 | Broncus Technologies, Inc. | Bronchial stenter |
US6200333B1 (en) | 1997-04-07 | 2001-03-13 | Broncus Technologies, Inc. | Bronchial stenter |
US6283988B1 (en) | 1997-04-07 | 2001-09-04 | Broncus Technologies, Inc. | Bronchial stenter having expandable electrodes |
US7027869B2 (en) | 1998-01-07 | 2006-04-11 | Asthmatx, Inc. | Method for treating an asthma attack |
US6411852B1 (en) | 1997-04-07 | 2002-06-25 | Broncus Technologies, Inc. | Modification of airways by application of energy |
US6045549A (en) | 1997-09-30 | 2000-04-04 | Somnus Medical Technologies, Inc. | Tissue ablation apparatus and device for use therein and method |
US7921855B2 (en) | 1998-01-07 | 2011-04-12 | Asthmatx, Inc. | Method for treating an asthma attack |
US6003517A (en) | 1998-04-30 | 1999-12-21 | Ethicon Endo-Surgery, Inc. | Method for using an electrosurgical device on lung tissue |
US6493589B1 (en) | 1998-05-07 | 2002-12-10 | Medtronic, Inc. | Methods and apparatus for treatment of pulmonary conditions |
US8181656B2 (en) | 1998-06-10 | 2012-05-22 | Asthmatx, Inc. | Methods for treating airways |
US20070106348A1 (en) | 1998-06-10 | 2007-05-10 | Asthmatx, Inc. | Method for treating airways in the lung |
US6767544B2 (en) * | 2002-04-01 | 2004-07-27 | Allergan, Inc. | Methods for treating cardiovascular diseases with botulinum toxin |
US6679264B1 (en) | 2000-03-04 | 2004-01-20 | Emphasys Medical, Inc. | Methods and devices for use in performing pulmonary procedures |
US6770070B1 (en) | 2000-03-17 | 2004-08-03 | Rita Medical Systems, Inc. | Lung treatment apparatus and method |
US8251070B2 (en) | 2000-03-27 | 2012-08-28 | Asthmatx, Inc. | Methods for treating airways |
US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
US8389700B2 (en) * | 2002-09-23 | 2013-03-05 | Alcatel Lucent | Agent delivery system capable of selectively releasing an agent |
US6974579B2 (en) * | 2004-01-08 | 2005-12-13 | Allergan, Inc. | Methods for treating vascular disorders |
US7906124B2 (en) * | 2004-09-18 | 2011-03-15 | Asthmatx, Inc. | Inactivation of smooth muscle tissue |
US20080004596A1 (en) | 2006-05-25 | 2008-01-03 | Palo Alto Institute | Delivery of agents by microneedle catheter |
US7900814B2 (en) * | 2007-11-01 | 2011-03-08 | Mcbride Ruby | File folder |
-
2004
- 2004-09-30 US US10/954,895 patent/US7906124B2/en active Active
-
2011
- 2011-02-01 US US13/018,713 patent/US8828945B2/en active Active
-
2014
- 2014-07-30 US US14/447,098 patent/US20140341801A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303145B2 (en) * | 1999-05-10 | 2001-10-16 | Sepracor Inc. | (S,R) formoterol methods and compositions |
Non-Patent Citations (9)
Title |
---|
Amoako et al. 1996; Probing excitation-contraction coupling in trachealis smooth muscle with mycotoxin cyclopiazonic acid. Clinical and Experimental Pharmacology and Physiology. 23: 733-737. * |
Cazzola et al. (2012; Pharmacology and therapeutics of bronchodilators. Pharmacological Reviews. 64(2): 450-504 * |
Cytoskeletal Drugs 2015; at en.wikipedia.org/wiki/Cytoskeltal_drugs. * |
Cytoskeleton, Inc. 2015; at cytoskeletal.com/custom-servies2-compound-screening-kinesin-myosin-assay. * |
Koh et al. 2006; Snake venom components and their applications in biomedicine. Cell Mol. Life Sci 63: 3030-3041. * |
Lafferty et al. 2015; Medications used in tracheal intubation. At emedicine.medscape.com/article/109739-overview. * |
Lim et al. 2006; Botulinum toxin: A novel therapetyci option for brochial asthma? Medical Hypothesis. 66: 915-919. * |
Mumtaz et al. 2009; Radioiodine I-131 for the therapy of Graves' Disease. Malaysian Journal of Medical Sciences. 16(1): 25-33. * |
Oltmanns et al. 2005; Induction of human airway smooth muscle apoptosis by neutrophils and neutrophil elastase. Am J. Respiratory and cell molecular biology. 32: 334-340. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10702337B2 (en) | 2016-06-27 | 2020-07-07 | Galary, Inc. | Methods, apparatuses, and systems for the treatment of pulmonary disorders |
US10939958B2 (en) | 2016-06-27 | 2021-03-09 | Galary, Inc. | Methods, apparatuses, and systems for the treatment of pulmonary disorders |
US11369433B2 (en) | 2016-06-27 | 2022-06-28 | Galvanize Therapeutics, Inc. | Methods, apparatuses, and systems for the treatment of pulmonary disorders |
Also Published As
Publication number | Publication date |
---|---|
US8828945B2 (en) | 2014-09-09 |
US20110184330A1 (en) | 2011-07-28 |
US7906124B2 (en) | 2011-03-15 |
US20060062808A1 (en) | 2006-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8828945B2 (en) | Inactivation of smooth muscle tissue | |
Xu et al. | Magnetic resonance imaging-guided laser interstitial thermal therapy for the treatment of hypothalamic hamartomas: a retrospective review | |
US9358153B2 (en) | Inhibition of platelet activation, aggregation and/or adhesion by hypothermia | |
Kryger et al. | The effects of VEGF on survival of a random flap in the rat: examination of various routes of administration | |
Tuominen et al. | Continuous interscalene brachial plexus block: clinical efficacy, technical problems and bupivacaine plasma concentrations | |
Wagle et al. | Long-term outcome of cyclocryotherapy for refractory pediatric glaucoma | |
US7542802B2 (en) | Methods of regenerating tissue in airways | |
Bown et al. | Endoscopic laser treatment of vascular anomalies of the upper gastrointestinal tract. | |
US8459268B2 (en) | Methods for treating airways | |
Mirski et al. | Interruption of the connections of the mammillary bodies protects against generalized pentylenetetrazol seizures in guinea pigs | |
Lahiri et al. | Experience with difficult keloids | |
Hendrix et al. | Papaverine-induced mydriasis. | |
EP0592903A2 (en) | Use of ancrod for the preparation of drugs for the treatment of restenosis | |
Svendsen et al. | Direct puncture of large arteriovenous malformations in head and neck for embolisation and subsequent reconstructive surgery | |
MILLER et al. | Complications of balloon catheterization associated with aberrant cerebral arterial anatomy in a horse with guttural pouch mycosis | |
Benson | Regional chemotherapy and local cryotherapy for cancer | |
Widdison et al. | The low-pressure duct perfusion model of acute pancreatitis | |
Conard et al. | Delayed recognition of podophyllum toxicity in a patient receiving epidural morphine | |
Katz et al. | Extracorporeal shock wave lithotripsy for treatment of ureterolithiasis in patients with cystinuria | |
RU2768463C1 (en) | Method for acute pancreatitis treatment | |
Gabrhelik et al. | Radiofrequency upper thoracic sympathectomy in the treatment of critical upper limb ischemia--a case series. | |
Barua et al. | Management of late hemorrhagic radiation cystitis in patients of carcinoma cervix with special reference to 1% alum irrigation and its safety: a clinical study in a tertiary care centre | |
POWERS JR | The maintenance of renal function following massive trauma | |
THIBAULT | Sclerotherapy and ultrasound-guided sclerotherapy | |
Upadhyay et al. | A case study illustrating the use of an integrated approach to treat secondary Anal Fistula Post I&D of Perianal Abscess |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |